Jaguar Health Strengthens IP with New Patent for Crofelemer in Intestinal Disorders

Jaguar Health, Inc. announced the acquisition of a new patent from the Australian Patent Office for its drug, crofelemer, targeting short bowel syndrome (SBS) and other intestinal disorders. This extends Jaguar's international IP protection, enhancing crofelemer's market position.

Crofelemer, a plant-based drug, has demonstrated potential in reducing parenteral support needs in pediatric patients with SBS and the ultra-rare Microvillus Inclusion Disease (MVID). Initial trial results in the UAE showed promising reductions in necessary intravenous support and improved stool consistency.

SBS affects up to 20,000 individuals in the US, while MVID remains an ultra-rare condition without approved treatments. Jaguar is conducting further trials in the US and EU to validate crofelemer's efficacy.

These efforts align with Jaguar Health's strategy to bolster its IP portfolio, having already secured approximately 195 patents globally, positioning crofelemer as a leading treatment option for rare gastrointestinal disorders.